Alkali Therapy in Chronic Kidney Disease

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT01452412

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01452412
Other papers using this trial's data
  • Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020-02 DOI, PubMed 31699517, PMC7012673 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01452412. Randomized; quadruple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2016-08 (actual). Results posted on 2020-01-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alkali Therapy in Chronic Kidney Disease
Condition
Metabolic Acidosis
Intervention (Drug)
Sodium bicarbonate
Intervention (Drug)
Placebo
Lead sponsor
Albert Einstein College of Medicine (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)
Collaborator
National Institutes of Health (NIH) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01452412
Content hash
9fc203269163420bec57d90e27eefee0583c27b6a3b61e4277e320eec0b49b4b